<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775264</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-001</org_study_id>
    <nct_id>NCT04775264</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of Atrial Deganglionation as Adjunctive Therapy for AF</brief_title>
  <acronym>Neural-AF</acronym>
  <official_title>Safety and Feasibility of Atrial Deganglionation as Adjunctive Therapy for Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrian Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrian Medical Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single arm, multi-center exploratory study of safety and feasibility in the&#xD;
      treatment of patients undergoing cardiothoracic surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and feasibility of electroporation/Pulsed Electric Field (PEF) as a&#xD;
      technology to achieve selective GP ablation. This treatment will be performed on 30 patients&#xD;
      undergoing cardiothoracic surgery. Primary feasibility endpoint will be demonstration of&#xD;
      ability to access and deliver Pulsed Electric Field energy to all of the targeted ablation&#xD;
      sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety device related events</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of device related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of delivering electric energy on the epicardial surface of the heart to eliminate AF</measure>
    <time_frame>intraprocedural</time_frame>
    <description>Confirmation of access and delivery of pulsed electric field energy to ablation sites</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Pulsed Electric Field Energy Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ablation of ganglionated plexi structures on the epicardial surface of the heart delivered as a concomitant procedure during open heart surgery to eliminate atrial fibrillation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pulsed electric field ablation</intervention_name>
    <description>catheter ablation of ganglionated plexi structures on the epicardial surface of the heart during cardiothoracic surgery</description>
    <arm_group_label>Pulsed Electric Field Energy Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age is between 18 and 70 years.&#xD;
&#xD;
          -  Scheduled for open-chest cardiothoracic surgery, for coronary artery bypass grafting.&#xD;
&#xD;
          -  Legally competent and willing to sign the informed consent.&#xD;
&#xD;
          -  Life expectancy of at least 2 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Previous cardiac surgery.&#xD;
&#xD;
               -  Prior pericardial interventions.&#xD;
&#xD;
               -  Prior pulmonary vein isolation (PVI).&#xD;
&#xD;
               -  Previous or existing pericarditis.&#xD;
&#xD;
               -  Persistent or long-standing persistent atrial fibrillation.&#xD;
&#xD;
               -  Indication for surgical ablation or PVI for atrial fibrillation.&#xD;
&#xD;
               -  Indication for concomitant surgical valve repair or replacement.&#xD;
&#xD;
               -  Indication for concomitant left atrial appendage (LAA) ligation or excision.&#xD;
&#xD;
               -  History of previous radiation therapy on the thorax.&#xD;
&#xD;
               -  History of previous thoracotomy.&#xD;
&#xD;
               -  Prior electrical or mechanical isolation of the Left Atrial Appendage (LAA).&#xD;
&#xD;
               -  The presence of LAA occlusion devices, coronary stents, prosthetic heart valves,&#xD;
                  pacemakers or implantable cardioverter defibrillators (ICDs).&#xD;
&#xD;
               -  Myocardial infarction within the previous 2 months.&#xD;
&#xD;
               -  NYHA Class IV heart failure symptoms.&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) &lt; 40%, measured by transthoracic&#xD;
                  echocardiography (TTE).&#xD;
&#xD;
               -  Left atrial (LA) diameter &gt; 5.0 cm, measured by transthoracic echocardiography&#xD;
                  (TTE).&#xD;
&#xD;
               -  The presence of left atrial thrombus when examined by transoesophageal&#xD;
                  echocardiography (TEE).&#xD;
&#xD;
               -  The presence of AF attributable to non-cardiovascular causes such as thyroid&#xD;
                  disease, electrolyte imbalance/dehydration or other reversible causes.&#xD;
&#xD;
               -  Active infection or sepsis as evidenced by increased white blood cell count,&#xD;
                  elevated CRP or temperature &gt; 38.5°C.&#xD;
&#xD;
               -  Known or documented carotid stenosis &gt; 80%&#xD;
&#xD;
               -  Stroke or transient ischemic attack within the previous 6 months.&#xD;
&#xD;
               -  Known or documented epilepsy.&#xD;
&#xD;
               -  Pregnancy or child-bearing potential without adequate contraception.&#xD;
&#xD;
               -  Circumstances that prevent follow-ups.&#xD;
&#xD;
               -  Drug abuse.&#xD;
&#xD;
               -  Patients cannot be enrolled in another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

